AU2014205441B2 - Methods for purification of arylsulfatase A - Google Patents

Methods for purification of arylsulfatase A Download PDF

Info

Publication number
AU2014205441B2
AU2014205441B2 AU2014205441A AU2014205441A AU2014205441B2 AU 2014205441 B2 AU2014205441 B2 AU 2014205441B2 AU 2014205441 A AU2014205441 A AU 2014205441A AU 2014205441 A AU2014205441 A AU 2014205441A AU 2014205441 B2 AU2014205441 B2 AU 2014205441B2
Authority
AU
Australia
Prior art keywords
chromatography
protein
column
asa
arylsulfatase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014205441A
Other languages
English (en)
Other versions
AU2014205441A1 (en
Inventor
Bee Lin CHEANG
Mei Huei JANG
Dave Nichols
Igor Quinones-Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2014205441A1 publication Critical patent/AU2014205441A1/en
Application granted granted Critical
Publication of AU2014205441B2 publication Critical patent/AU2014205441B2/en
Priority to AU2020201079A priority Critical patent/AU2020201079B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: SHIRE HUMAN GENETIC THERAPIES, INC.
Priority to AU2022221475A priority patent/AU2022221475B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014205441A 2013-01-09 2014-01-09 Methods for purification of arylsulfatase A Ceased AU2014205441B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020201079A AU2020201079B2 (en) 2013-01-09 2020-02-14 Methods for purification of arylsulfatase a
AU2022221475A AU2022221475B2 (en) 2013-01-09 2022-08-25 Methods for purification of arylsulfatase a

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
US61/750,693 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201079A Division AU2020201079B2 (en) 2013-01-09 2020-02-14 Methods for purification of arylsulfatase a

Publications (2)

Publication Number Publication Date
AU2014205441A1 AU2014205441A1 (en) 2015-06-25
AU2014205441B2 true AU2014205441B2 (en) 2019-12-12

Family

ID=50002885

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014205441A Ceased AU2014205441B2 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase A
AU2020201079A Ceased AU2020201079B2 (en) 2013-01-09 2020-02-14 Methods for purification of arylsulfatase a
AU2022221475A Ceased AU2022221475B2 (en) 2013-01-09 2022-08-25 Methods for purification of arylsulfatase a

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020201079A Ceased AU2020201079B2 (en) 2013-01-09 2020-02-14 Methods for purification of arylsulfatase a
AU2022221475A Ceased AU2022221475B2 (en) 2013-01-09 2022-08-25 Methods for purification of arylsulfatase a

Country Status (12)

Country Link
US (3) US11407984B2 (enExample)
EP (1) EP2943568B1 (enExample)
JP (5) JP6427502B2 (enExample)
CN (4) CN119979504A (enExample)
AU (3) AU2014205441B2 (enExample)
BR (1) BR112015015948B1 (enExample)
CA (1) CA2896979C (enExample)
EA (1) EA030551B1 (enExample)
ES (1) ES2768261T3 (enExample)
HK (1) HK1214622A1 (enExample)
MX (2) MX372711B (enExample)
WO (1) WO2014110246A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
CN108473558A (zh) * 2015-08-20 2018-08-31 豪夫迈·罗氏有限公司 Fkpa的纯化及其用于生产重组多肽的用途
CA3015685A1 (en) * 2016-03-16 2017-09-21 Phoenix Tissue Repair, Inc. Methods of purifying collagen 7
CN111065735B (zh) * 2017-08-31 2023-07-07 株式会社绿十字 用于纯化硫酸酯酶蛋白的方法
CA3086181A1 (en) * 2017-12-19 2019-06-27 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof
RU2020118032A (ru) * 2018-02-02 2022-03-02 Асераген, Инк. Способы лечения болезни фарбера
EP3774894A1 (en) 2018-04-12 2021-02-17 Amgen Inc. Methods for making stable protein compositions
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
EP4072600A1 (en) * 2019-12-12 2022-10-19 Eli Lilly and Company Methods for viral inactivation by environmentally compatible detergents
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659B (zh) * 2023-07-11 2025-03-28 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法
EP4778935A1 (en) * 2025-01-15 2026-07-22 Sartorius Stedim Biotech GmbH Method for purifying a target product

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456229A2 (en) * 1990-05-10 1991-11-13 Bristol-Myers Squibb Company Arylsulfatase
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2005073367A1 (en) * 2004-01-30 2005-08-11 Zymenex A/S Production and purification of recombinant arylsulfatase a

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
ATE217799T1 (de) 1998-01-27 2002-06-15 Hemebiotech As Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
ID27417A (id) 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
AU774603B2 (en) 1999-07-27 2004-07-01 Zymenex A/S Production of rhPBGD and new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1409695A2 (en) 2000-11-15 2004-04-21 Genzyme Corporation Expression system for recombinant proteins
WO2002099092A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
WO2003002731A1 (en) 2001-06-29 2003-01-09 Hemebiotech A/S A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
PL1740204T3 (pl) 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
NO347673B1 (no) 2006-04-04 2024-02-19 Takeda Pharmaceuticals Co En sammensetning som omfatter konsentrert polypeptide og bruk derav.
CN105646643A (zh) * 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
JP6045493B2 (ja) * 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａのｃｎｓ送達の方法および組成物
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456229A2 (en) * 1990-05-10 1991-11-13 Bristol-Myers Squibb Company Arylsulfatase
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2005073367A1 (en) * 2004-01-30 2005-08-11 Zymenex A/S Production and purification of recombinant arylsulfatase a

Also Published As

Publication number Publication date
EA201590826A1 (ru) 2015-11-30
JP2024001160A (ja) 2024-01-09
MX2020003798A (es) 2020-08-03
HK1216429A1 (en) 2016-11-11
WO2014110246A1 (en) 2014-07-17
CN119979504A (zh) 2025-05-13
ES2768261T3 (es) 2020-06-22
AU2022221475B2 (en) 2025-05-22
EA030551B1 (ru) 2018-08-31
CA2896979A1 (en) 2014-07-17
JP6427502B2 (ja) 2018-11-21
CN112126634A (zh) 2020-12-25
US11884945B2 (en) 2024-01-30
AU2020201079B2 (en) 2022-05-26
JP2016504040A (ja) 2016-02-12
BR112015015948A2 (enExample) 2017-08-15
US20240392268A1 (en) 2024-11-28
US11407984B2 (en) 2022-08-09
US20230235303A1 (en) 2023-07-27
JP2018171067A (ja) 2018-11-08
AU2020201079A1 (en) 2020-03-05
JP7663649B2 (ja) 2025-04-16
CN120665836A (zh) 2025-09-19
JP7407161B2 (ja) 2023-12-28
US12319940B2 (en) 2025-06-03
MX372711B (es) 2020-04-21
HK1214622A1 (zh) 2016-07-29
EP2943568B1 (en) 2019-11-20
JP2020015750A (ja) 2020-01-30
CN104903442A (zh) 2015-09-09
CA2896979C (en) 2023-05-02
US20150353904A1 (en) 2015-12-10
BR112015015948B1 (pt) 2022-05-17
AU2022221475A1 (en) 2022-09-22
AU2014205441A1 (en) 2015-06-25
MX2015008875A (es) 2015-10-22
EP2943568A1 (en) 2015-11-18
JP2022023225A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
US12319940B2 (en) Methods for purification of arylsulfatase A
AU2018200230B2 (en) Purification of iduronate-2-sulfatase
EP2729566B1 (en) Methods for purification of arylsulfatase a
HK1216429B (en) Methods for purification of arylsulfatase a
WO2024176112A1 (en) Large scale production of recombinant arylsulfatase a and compositions thereof
AU2018393045A1 (en) Purified arylsulfatase A and compositons thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): SHIRE HUMAN GENETIC THERAPIES, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired